2022
Inhaled Bacteriophage Therapy for Multi-Drug Resistant Achromobacter.
Winzig F, Gandhi S, Lee A, Würstle S, Stanley G, Capuano I, Neuringer I, Koff J, Turner P, Chan B. Inhaled Bacteriophage Therapy for Multi-Drug Resistant Achromobacter. The Yale Journal Of Biology And Medicine 2022, 95: 413-427. PMID: 36568830, PMCID: PMC9765334.Peer-Reviewed Original ResearchConceptsCF patientsCystic fibrosisChronic pulmonary infectionGlobal public health threatBacterial lung infectionsChallenging clinical problemPublic health threatChronic bacterial lung infectionsPulmonary infectionRespiratory statusLung infectionClinical problemBacteriophage therapyInfectionAntimicrobial-resistant bacteriaTherapyHealth threatPhage therapyPatientsAMR infectionsResistant bacteriaLytic bacteriophagesPossible benefitsChemical antibioticsCurrent study
2020
Multi-dimensional clinical phenotyping of a national cohort of adult cystic fibrosis patients
Conrad D, Billings J, Teneback C, Koff J, Rosenbluth D, Bailey B, Jain R. Multi-dimensional clinical phenotyping of a national cohort of adult cystic fibrosis patients. Journal Of Cystic Fibrosis 2020, 20: 91-96. PMID: 32948498, DOI: 10.1016/j.jcf.2020.08.010.Peer-Reviewed Original ResearchConceptsCystic fibrosis transmembrane conductance regulatorCF patientsCystic fibrosisClinical phenotypeChronic P. aeruginosa infectionDistal intestinal obstruction syndromeAdult cystic fibrosis patientsPseudomonas aeruginosa colonizationUS CF centersAdult CF patientsIntestinal obstruction syndromeTransmembrane conductance regulatorHigh-risk phenotypeWell-nourished groupCholestatic liver diseaseGroup of patientsCystic fibrosis patientsRates of pancreatic insufficiencyMulti-system disorderPancreatic malabsorptionObstruction syndromeChronic sinusitisConductance regulatorPancreatic insufficiencyCF centers